SCM
Sarissa Capital Management Portfolio holdings
AUM
$154M
This Quarter Return
+3.81%
1 Year Return
-6.05%
3 Year Return
-7.91%
5 Year Return
+32.47%
10 Year Return
+262.41%
AUM
$1.06B
AUM Growth
+$1.06B
(-8.4%)
Cap. Flow
-$106M
Cap. Flow
% of AUM
-10.05%
Top 10 Holdings %
Top 10 Hldgs %
99.95%
Holding
11
New
–
Increased
1
Reduced
2
Closed
–
Top Buys
| 1 |
AMRN
Amarin Corp
AMRN
|
$15.6M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$78.9M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
$43.1M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Alkermes
ALKS
$4.78B
| $369M | 34.92% | 14,040,000 | – | – |
|
2
Ironwood Pharmaceuticals
IRWD
$214M
| $206M | 19.49% | 16,390,000 | – | – |
|
3
Biogen
BIIB
$19.4B
| $135M | 12.8% | 643,000 | – | – |
|
4
Innoviva
INVA
$1.29B
| $128M | 12.1% | 6,614,000 | – | – |
|
|
5
Gilead Sciences
GILD
$140B
| $92.9M | 8.78% | 1,562,900 -1,326,400 | -46% | -$78.9M |
|
|
AMRN
6
Amarin Corp
AMRN
$311M
| $79M | 7.46% | 24,000,000 +4,750,000 | +25% | +$15.6M |
|
|
7
BioCryst Pharmaceuticals
BCRX
$1.74B
| $22.6M | 2.14% | 1,390,790 -2,648,810 | -66% | -$43.1M |
|
8
Mersana Therapeutics
MRSN
$36.5M
| $17.2M | 1.62% | 4,299,297 | – | – |
|
9
Vor Biopharma
VOR
$250M
| $4.27M | 0.4% | 707,010 | – | – |
|
|
PEAR
10
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
| $2.53M | 0.24% | 500,356 | – | – |
|
|
RGLS
11
DELISTED
Regulus Therapeutics
RGLS
| $552K | 0.05% | 1,851,851 | – | – |
|